• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.

作者信息

Zhang Yaguang, Wang Xiaojing, Li Xuezhen, Xi Dong, Mao Ruizhi, Wu Xiaohui, Cheng Shipeng, Sun Xiaoyu, Yi Chunyan, Ling Zhiyang, Ma Liyan, Ning Qin, Fang Yiru, Sun Bing, Wu Di

机构信息

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.

Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.

出版信息

Cell Mol Immunol. 2020 Aug;17(8):878-880. doi: 10.1038/s41423-020-0484-x. Epub 2020 Jun 25.

DOI:10.1038/s41423-020-0484-x
PMID:32587367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7315399/
Abstract
摘要

相似文献

1
Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.可溶性白细胞介素-2受体增加对COVID-19患者淋巴细胞减少的潜在作用。
Cell Mol Immunol. 2020 Aug;17(8):878-880. doi: 10.1038/s41423-020-0484-x. Epub 2020 Jun 25.
2
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.利用 IL-2R/淋巴细胞预测 COVID-19 患者的临床进展。
Clin Exp Immunol. 2020 Jul;201(1):76-84. doi: 10.1111/cei.13450. Epub 2020 May 15.
3
Cellular immune responses to covid-19.对新冠病毒的细胞免疫反应。
BMJ. 2020 Jul 31;370:m3018. doi: 10.1136/bmj.m3018.
4
Systemically comparing host immunity between survived and deceased COVID-19 patients.系统比较新冠病毒肺炎幸存者与死亡患者之间的宿主免疫力。
Cell Mol Immunol. 2020 Aug;17(8):875-877. doi: 10.1038/s41423-020-0483-y. Epub 2020 Jun 15.
5
What the immune response to the coronavirus says about the prospects for a vaccine.对冠状病毒的免疫反应揭示了疫苗的前景。
Nature. 2020 Sep;585(7823):20-21. doi: 10.1038/d41586-020-02400-7.
6
The inhibition of IL-2/IL-2R gives rise to CD8 T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.在 COVID-19 肺炎的危重症患者中，通过 JAK1-STAT5 抑制 IL-2/IL-2R 会导致 CD8 T 细胞和淋巴细胞减少。
Cell Death Dis. 2020 Jun 8;11(6):429. doi: 10.1038/s41419-020-2636-4.
7
The changes of the peripheral CD4+ lymphocytes and inflammatory cytokines in Patients with COVID-19.新型冠状病毒肺炎患者外周血 CD4+T 淋巴细胞及炎症因子的变化。
PLoS One. 2020 Sep 25;15(9):e0239532. doi: 10.1371/journal.pone.0239532. eCollection 2020.
8
The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives.新型冠状病毒肺炎大流行：镁有作用吗？假说与展望。
Magnes Res. 2020 May 1;33(2):21-27. doi: 10.1684/mrh.2020.0465.
9
COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury.新冠病毒疾病的严重程度与较弱的T细胞免疫、高细胞因子血症以及肺上皮损伤相关。
Am J Respir Crit Care Med. 2020 Aug 15;202(4):606-610. doi: 10.1164/rccm.202005-1701LE.
10
Comparison of the diagnostic performance with whole blood and plasma of four rapid antibody tests for SARS-CoV-2.四种SARS-CoV-2快速抗体检测方法对全血和血浆诊断性能的比较。
Clin Chem Lab Med. 2020 Sep 25;58(10):e197-e199. doi: 10.1515/cclm-2020-0817.

引用本文的文献

1
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.共价研究：新冠病毒mRNA疫苗在转移性肺癌长期存活患者开放标签队列中的免疫原性和反应原性
Vaccines (Basel). 2025 Mar 5;13(3):273. doi: 10.3390/vaccines13030273.
2
The effect of therapeutic plasma exchange on the inflammatory response in septic shock: a secondary analysis of the EXCHANGE-1 trial.治疗性血浆置换对脓毒性休克炎症反应的影响：EXCHANGE-1试验的二次分析
Intensive Care Med Exp. 2025 Feb 14;13(1):18. doi: 10.1186/s40635-025-00725-z.
3
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.

本文引用的文献

1
COVID-19 and Kawasaki Disease: Novel Virus and Novel Case.新型冠状病毒肺炎与川崎病：新型病毒与新型病例。
Hosp Pediatr. 2020 Jun;10(6):537-540. doi: 10.1542/hpeds.2020-0123. Epub 2020 Apr 7.
2
Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.血浆中可溶性白细胞介素-2受体浓度升高预示着细胞对白细胞介素-2的反应降低。
Br J Cancer. 1995 Aug;72(2):452-5. doi: 10.1038/bjc.1995.354.
中国奥密克戎流行期间，重症和危重症奥密克戎感染患者的免疫和炎症特征。
BMC Infect Dis. 2024 Aug 9;24(1):809. doi: 10.1186/s12879-024-09652-y.
4
Elevated CD4 T Cell Senescence Associates with Impaired Immune Responsiveness in Severe COVID-19.CD4 T细胞衰老加剧与重症COVID-19患者免疫反应受损有关。
Aging Dis. 2024 Feb 17;16(1):498-511. doi: 10.14336/AD.2024.0214-2.
5
Integrated analysis of RNA-seq datasets reveals novel targets and regulators of COVID-19 severity.RNA-seq 数据集的综合分析揭示了 COVID-19 严重程度的新靶点和调控因子。
Life Sci Alliance. 2024 Jan 23;7(4). doi: 10.26508/lsa.202302358. Print 2024 Apr.
6
COVID severity test (CoST sensor)-An electrochemical immunosensing approach to stratify disease severity.新冠严重程度测试（CoST传感器）——一种用于分层疾病严重程度的电化学免疫传感方法。
Bioeng Transl Med. 2023 Jul 11;8(5):e10566. doi: 10.1002/btm2.10566. eCollection 2023 Sep.
7
Frequency of HLA-DRCD38 T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders.HLA-DRCD38 T 细胞的频率可识别和定量噬血细胞性淋巴组织细胞增生症、炎症过度活跃和免疫调节障碍中的 T 细胞活化。
J Allergy Clin Immunol. 2024 Jan;153(1):309-319. doi: 10.1016/j.jaci.2023.07.008. Epub 2023 Jul 29.
8
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).Ixekizumab 对比低剂量白细胞介素 2 对比秋水仙碱对比标准治疗用于治疗中重度 COVID-19 住院患者的疗效和安全性：一项先导随机临床试验（STRUCK：使用细胞因子抑制剂的生存试验）。
Rev Soc Bras Med Trop. 2023 Apr 14;56:e0565. doi: 10.1590/0037-8682-0565-2022. eCollection 2023.
9
Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.调节性T细胞（Tregs）与新冠病毒病（COVID-19）：揭示其机制及治疗潜力，特别关注新冠后综合征
Vaccines (Basel). 2023 Mar 19;11(3):699. doi: 10.3390/vaccines11030699.
10
Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25 regulatory and memory T cells.可溶性 CD25 形成低区 IL-2 信号环境，有利于抗原经验的 CD25 调节性和记忆 T 细胞的竞争生长。
Cell Immunol. 2023 Feb;384:104664. doi: 10.1016/j.cellimm.2023.104664. Epub 2023 Jan 5.